Table 3.
Clinical and pathological features compared between PSP/AD and PSP
| Features | PSP/AD | PSP | P value |
|---|---|---|---|
| Main cohort | N = 15 | N = 106 | |
| Disease duration, years | 9 (6, 13) | 7 (5, 9) | 0.10 |
| Age at death, years | 81 ± 6 | 73 ± 8 | <0.001 |
| Braak neurofibrillary tangle stage | IV (IV, V) | II (I, III) | <0.001 |
| Thal amyloid phase | 4 (3, 4) | 0 (0, 2) | <0.001 |
| Total tau burden | 1.4 ± 0.4 | 1.6 ± 0.3 | 0.03 |
| Cognitive impairment | 9 (60%) | 81 (76%) | 1.00 |
| Subgroup patients | N = 6 | N = 31 | |
| Disease duration | 8 (6, 10) | 7 (5, 9) | 0.62 |
| Age at death | 79 ± 7 | 74 ± 7 | 0.13 |
| Braak neurofibrillary tangle stage | IV (IV, V) | II (II, III) | <0.001 |
| Thal amyloid phase | 4 (3, 4) | 0 (0, 3) | <0.001 |
| Total tau burden | 1.5 ± 0.4 | 1.6 ± 0.4 | 0.47 |
| Overall Test Battery Mean | 43 (32, 51) | 40 (33, 47) | 0.72 |
| Attention/Processing Speed | 47 (35, 48) | 44 (37, 50) | 0.84 |
| Executive Functioning | 46 (26, 47) | 37 (28, 45) | 0.88 |
| Episodic Memory | 32 (28, 59) | 46 (35, 54) | 0.48 |
| Language | 42 (35, 51) | 43 (36, 47) | 1.00 |
| Visuospatial/Construction | 44 (35, 48) | 43 (35, 47) | 0.98 |
Overall Test Battery Mean and domain mean score are available for 5 patients in PSP/AD and 27 patients in PSP. Abbreviation: PSP, progressive supranuclear palsy; PSP/AD, PSP with Alzheimer’s disease.